# FOXO TECHNOLOGIES INC. (FOXOW) — divestiture/asset_sale [announced]
Source: SEC API (secapi.ai) · situation sit_d66f251f58a7e226e8cf · retrieved 2026-08-11T16:09:38.481Z

## Overview
FOXO Technologies Inc. is a commercial physical and biological research services company; its subsidiary Vector BioSource collects and distributes whole blood as research-use-only biospecimens.

Vector BioSource, Inc., a subsidiary of FOXO Technologies Inc., entered into an asset purchase agreement on July 22, 2026 to acquire four U.S.-based blood collection centers from Grifols Bio Supplies, Inc. (a subsidiary of Grifols S.A.). The transaction provides for upfront cash consideration of $3,500,000 payable at closing, plus a contingent earn-out payment of up to $1,000,000 in cash. The full earn-out becomes payable if the acquired business generates EBITDA of $1,500,000 or more in any single calendar year during the earn-out period covering calendar years 2026, 2027, and 2028. Closing is expected in the third or fourth quarter of 2026, subject to customary closing conditions including Vector obtaining new FDA licenses, CLIA certifications, and waste-management permits independent of the Seller's existing authorizations.

## Terms
- Counterparty: Grifols Bio Supplies, Inc. · Consideration: cash

## Key dates
- Announced 2026-07-27 · Expiry 2027-04-22

## Timeline
- 2026-07-27 · 8-K (0001493152-26-034793): 8-K - FOXO TECHNOLOGIES INC. — *FOXO Technologies Inc. is a commercial physical and biological research services company; its subsidiary Vector BioSource collects and distributes whole blood as research-use-only biospecimens.* Vector BioSource, Inc., a subsidiary of FOXO Technologies Inc., entered into an asset purchase agreement on July 22, 2026 to acquire four U.S.-based blood collection centers from Grifols Bio Supplies, Inc. (a subsidiary of Grifols S.A.). The transaction provides for upfront cash consideration of $3,500,000 payable at closing, plus a contingent earn-out payment of up to $1,000,000 in cash. The full earn-out becomes payable if the acquired business generates EBITDA of $1,500,000 or more in any single calendar year during the earn-out period covering calendar years 2026, 2027, and 2028. Closing is expected in the third or fourth quarter of 2026, subject to customary closing conditions including Vector obtaining new FDA licenses, CLIA certifications, and waste-management permits independent of the Seller's existing authorizations.
  https://www.sec.gov/Archives/edgar/data/1812360/0001493152-26-034793.txt

## Citations
- 0001493152-26-034793 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000149315226034793